Evidence map›Paper›PMID 39951615›Full record

ArticleBlood advances2025

Characterizing the heterogeneity of Castleman disease and oligocentric subtype: findings from the ACCELERATE registry.

Sheila K Pierson, Joshua D Brandstadter, Drew A Torigian, Adam Bagg, Mary Jo Lechowicz, Daisy Alapat, Corey Casper, Amy Chadburn, Shanmuganathan Chandrakasan, Angela Dispenzieri and 18 more

Abstract read
In one paragraph

Article in Blood advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Snapshot Look at Castleman Disease.Journal of cellular and molecular medicine · 2026
    Review
  5. Article
  6. Article
  7. Article
  8. Expert Perspective: Diagnosis and Treatment of Castleman Disease.Arthritis & rheumatology (Hoboken, N.J.) · 2026
    Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Sheila K PiersonCenter for Cytokine Storm Treatment & Laboratory, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.ORCID 0000-0002-3736-1411
Joshua D BrandstadterDivision of Hematology/Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.ORCID 0000-0003-0652-5791
Drew A TorigianDepartment of Radiology, Hospital of the University of Pennsylvania, Philadelphia, PA.ORCID 0000-0001-8999-9735
Adam BaggDepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA.ORCID 0000-0002-1669-468X
Mary Jo LechowiczDepartment of Hematology and Medical Oncology, Emory University School of Medicine and Winship Cancer Institute, Atlanta, GA.ORCID 0000-0003-1997-1950
Daisy AlapatDepartment of Pathology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR.ORCID 0000-0002-3414-8375
Corey CasperAccess to Advanced Health Institute, Seattle, WA.ORCID 0000-0002-3609-661X
Amy ChadburnDivision of Hematopathology, Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY.ORCID 0000-0002-9499-8638
Shanmuganathan ChandrakasanDepartment of Pediatrics, Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta and Emory University, Atlanta, GA.ORCID 0000-0001-8007-9932
Angela DispenzieriDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.ORCID 0000-0001-8780-9512
Alexander FossåDepartment of Oncology, Oslo University Hospital, Oslo, Norway.ORCID 0000-0002-4484-9319
Christian HoffmannICH Hamburg Study Center, Hamburg, Germany.ORCID 0000-0002-1082-8093
Makoto IdeDepartment of Hematology, Takamatsu Red Cross Hospital, Takamatsu, Japan.ORCID 0000-0002-5296-7518
Razelle KurzrockDepartment of Medicine, Medical College of Wisconsin, Milwaukee, WI.ORCID 0000-0003-4110-1214
Sudipto MukherjeeDepartment of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH.ORCID 0000-0002-8325-2603
Sunita NastaAbramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.ORCID 0000-0002-8981-2931
José-Tomás NavarroDepartment of Hematology-Laboratory, Institut Català d'Oncologia-Germans Trias i Pujol Hospital, Josep Carreras Leukaemia Research Institute, Universitat Autònoma de Barcelona, Badalona, Spain.ORCID 0000-0001-9101-6013
Ariela NoyLymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0002-3001-4898
Eric OksenhendlerDepartment of Clinical Immunology, Hôpital Saint-Louis, Paris, France.ORCID 0000-0001-8588-7138
Mateo Sarmiento BustamanteCenter for Cytokine Storm Treatment & Laboratory, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.ORCID 0009-0002-6774-2714
Saishravan ShyamsundarCenter for Cytokine Storm Treatment & Laboratory, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.ORCID 0000-0002-0160-8910
Matthew StreetlyClinical Haematology, Guy's Hospital, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Raymond S M WongSir Y.K. Pao Centre for Cancer and Department of Medicine & Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China.ORCID 0000-0002-9011-4268
Lu ZhangDepartment of Haematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Megan S LimDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York City, NY.ORCID 0000-0002-0415-2867
Gordan SrkalovicUniversity of Michigan Health-Sparrow Herbert-Herman Cancer Center, Lansing, MI.ORCID 0000-0003-3519-0409
Frits van RheeMyeloma Center, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR.ORCID 0000-0001-9959-1282
David C FajgenbaumCenter for Cytokine Storm Treatment & Laboratory, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.ORCID 0000-0002-7367-8184

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
mTOR as a Central Regulator of iMCD Pathogenesis and Novel Therapeutic TargetR01HL141408 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI Taku Kambayashi · 2018 to 2026
$6.1M
FDA HHS R01 FD007632NCI NIH HHS P30 CA008748NHLBI NIH HHS R01 HL141408
6 · The paper itself

Abstract

abstractCastleman disease (CD) describes a group of rare lymphoproliferative disorders that exhibit a wide range of symptomatology and degree of lymphadenopathy, particularly across the 2 forms of CD with unknown etiology, unicentric CD (UCD), and human herpesvirus-8-negative/idiopathic multicentric CD (iMCD). Whereas UCD cases typically present with localized lymphadenopathy and mild symptoms, iMCD involves multicentric lymphadenopathy and cytokine storm-driven symptoms with 3 recognized clinical phenotypes. Increasingly, there are anecdotal reports of cases that do not fit into this framework, but these cases have not been systematically described. Herein, we use the ACCELERATE natural history registry to characterize the spectrum of CD based on disease features, symptomatology, and severity. Our results characterize a cohort of 179 CD cases, which were reviewed and confirmed by an expert panel of clinicians and hematopathologists. We show that patients with CD present on a continuous spectrum of clinical phenotypes, and we describe oligocentric CD (OligoCD), an intermediate phenotype that does not fit the criteria for UCD or iMCD. These cases tend to have "oligocentric" lymphadenopathy (median [interquartile range] regions of lymphadenopathy, 3.0 [2.0-4.0]) in a regional pattern and exhibit a mild clinical phenotype that is more similar to UCD than iMCD. We also show that patients with OligoCD are inconsistently categorized as UCD vs iMCD, highlighting the need for this characterization. Future data collected through ACCELERATE may further elucidate the natural history and risk profile of these patients.

Indexed as

Castleman DiseaseAdolescentAdultAgedFemaleHumansMaleMiddle AgedPhenotypeRegistriesYoung Adult

Identifiers

PMID39951615
PMCPMC12018988

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.